Publication: 2623

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8
      QxMD      Google Scholar   
Citation:
Support Care Cancer vol 18 (3) 321-8
Year:
2010
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
CCP
Primary Committee:
Symptom Inter
Sec. Committees:
   
Pharmas:
 
Grants:
CA 124477, U10 CA035267, N01 CA035431, CA-37404, K05 CA124477, CA-63844, CA-35195, U10 CA037404, N01 CA035119, U10 CA035195, CA-25224, N01 CA063844, CA 35431, U10 CA035272, U10 CA035431, U10 CA035119, CA-35272, U10 CA025224, CA-35267, U10 CA063844  
Corr. Author:
 
Authors:
                     
Networks:
 
Study
NCCTG-N01C8
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords:
Prostate cancer, Androgen deprivation therapy, Osteoporosis, Risedronate, Estradiol